Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22342261 | 0.81 | CYP1A2 (0.44) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL7520769 | 0.81 | CYP1A2 (0.77) | CYP1A2CYP2C19CYP2C9ALDH1A1TDP1 | |
| SCHEMBL22341329 | 0.79 | CYP1A2 (0.39) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL8553919 | 0.74 | MAPT (0.40) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL20734670 | 0.74 | CYP1A2 (0.43) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL22341328 | 0.74 | CYP1A2 (0.44) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL8560261 | 0.73 | MAPT (0.39) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL3069772 | 0.73 | CYP1A2 (0.44) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 | |
| SCHEMBL12854049 | 0.71 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9ALDH1A1CYP2D6 | |
| SCHEMBL8050013 | 0.71 | HSD17B10 (0.50) | CYP1A2CYP2C19CYP2C9MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | ALMIRALL SA (ES) | 2020-08-13 | — | — | US | disclosed |
| WO-2019030298-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | ALMIRALL, S.A. (ES) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255478-A1 | NOVEL COMPOUNDS ACTIVATING THE NRF2 PATHWAY | KEAP1, NFE2L2, HMOX1 | CYP1A2 2291/4885CYP2C19 4101/4885CYP2C9 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.